From	O
therapeutic	O
antibodies	B:C0003241
to	O
chimeric	B:C4039583
antigen	I:C4039583
receptors	I:C4039583
(	O
chimeric	B:C4039583
antigen	I:C4039583
receptors	I:C4039583
)	O
:	O
making	O
better	O
chimeric	B:C4039583
antigen	I:C4039583
receptors	I:C4039583
based	O
on	O
antigen	B:C0003320
-	O
binding	B:C1514535
domain	I:C1514535
.	O

A	O
variety	O
of	O
approaches	O
are	O
being	O
pursued	O
to	O
improve	B:C0184511
the	O
safety	O
and	O
antitumor	B:C0243095
potency	I:C0243095
of	O
chimeric	B:C4289797
antigen	I:C4289797
receptor	I:C4289797
(	I:C4289797
CAR	I:C4289797
)	I:C4289797
T	I:C4289797
-	I:C4289797
cell	I:C4289797
therapy	I:C4289797
.	O

However	O
,	O
most	O
engineering	B:C0033629
efforts	I:C0033629
have	O
thus	O
far	O
been	O
focused	O
on	O
its	O
intracellular	B:C0178719
signaling	B:C0002518
domain	I:C0002518
,	O
while	O
its	O
extracellular	B:C0521119
antigen	B:C0003320
-	O
binding	B:C1514535
domain	I:C1514535
has	O
received	O
less	O
attention	O
.	O

Areas	O
covered	O
:	O
Herein	O
,	O
the	O
authors	B:C3812881
summarize	O
the	O
current	B:C0376554
knowledge	I:C0376554
of	O
CAR	B:C4289797
T	I:C4289797
-	I:C4289797
cell	I:C4289797
therapy	I:C4289797
.	O

Accordingly	O
,	O
they	O
focus	O
on	O
its	O
antigen	B:C0003320
-	O
binding	B:C1514535
domain	I:C1514535
,	O
discuss	O
key	B:C0518609
considerations	I:C0518609
for	O
selecting	O
an	O
optimal	O
single	B:C1883036
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	B:C1883036
)	O
when	O
designing	O
a	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
,	O
and	O
suggest	O
potential	O
directions	B:C0439755
aimed	O
at	O
developing	O
the	O
next	O
-	O
generation	O
chimeric	B:C4039583
antigen	I:C4039583
receptors	I:C4039583
.	O

The	O
extracellular	B:C0521119
region	I:C0521119
of	O
chimeric	B:C4039583
antigen	I:C4039583
receptors	I:C4039583
can	O
play	O
a	O
decisive	O
role	O
in	O
their	O
safety	O
and	O
efficacy	O
.	O

Instead	O
of	O
directly	O
translating	O
an	O
available	O
therapeutic	O
mAb	B:C0003250
to	O
a	O
scFv-based	B:C1883036
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
construct	O
,	O
the	O
authors	B:C3812881
suggest	O
that	O
various	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
-	O
displayed	O
scFvs	B:C1883036
with	O
different	O
affinity	O
,	O
specificity	O
and	O
binding	B:C1167622
epitopes	B:C0003316
against	O
an	O
individual	O
target	O
molecule	O
should	O
be	O
generated	O
and	O
evaluated	B:C0220825
side	O
-	O
by	O
-	O
side	O
.	O

Incorporating	O
new	O
antibody	B:C0003241
formats	I:C0003241
that	O
possess	O
characteristics	O
superior	B:C1282910
to	O
those	O
of	O
scFvs	B:C1883036
may	O
be	O
one	O
way	O
to	O
engineer	O
safer	O
and	O
more	O
effective	O
chimeric	B:C4039583
antigen	I:C4039583
receptors	I:C4039583
.	O

The	O
authors	B:C3812881
expect	O
that	O
further	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
engineering	B:C0033629
will	O
enable	O
us	O
to	O
target	O
more	O
antigens	B:C0003320
involved	O
in	O
hematological	B:C0376545
and	O
solid	B:C0006826
malignancies	I:C0006826
with	O
minimal	O
side	B:C0879626
effects	I:C0879626
to	O
serve	O
unmet	O
clinical	O
needs	O
.	O

